TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry announced the successful completion of its Annual General Meeting of shareholders held on June 9th, 2025. All matters brought before shareholders, as outlined in the Management Information Circular dated May 5, 2025, were duly approved. The shareholders ...